title: [Retrospective analysis of treatment outcomes in 70 patients with t(8;21) acute myeloid leukemia].
abstract: We conducted a retrospective study to evaluate outcomes and prognostic factors of newly diagnosed patients with t(8;21) acute myeloid leukemia (AML). There were 70 patients (43 men and 27 women) with a median age of 48 years old (range, 17∼76 years old). Sixty-five patients achieved complete remission (CR) after induction chemotherapy. Fifty-seven patients received consolidation chemotherapy based on the policy of not performing allogeneic hematopoietic stem cell transplantation (allo-HSCT) at the time of first CR. Twenty-seven of the 57 patients relapsed (relapse rate, 47%). The median time from the achievement of the first CR to relapse was 307 days (96∼1,256 days). A white blood cell count of more than 25,400/μl at diagnosis was associated with a higher relapse rate than a white blood cell count of less than or equal to 25,400/μl (75% vs. 43%, P=0.04). Nineteen of the 25 relapsed patients who received re-induction therapy experienced a second CR (second CR rate, 76%). Twenty-six patients (5 with first CR, 12 with second CR, and 9 without remission) received allo-HSCT. The five-year overall survival and disease-free survival rates were 61% and 45%, respectively. Patients with t(8;21) AML had a high CR rate, but about half of them relapsed. However, this report could not show prognostic factors for the identification of patients who should receive allo-HSCT at the time of their first CR.
authors.affiliation: Department of Hematology, Kanagawa Cancer Center.
authors.forename: Ayumi
authors.initials: A
authors.lastname: Numata
authors.forename: Katsumichi
authors.initials: K
authors.lastname: Fujimaki
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Aoshima
authors.forename: Makoto
authors.initials: M
authors.lastname: Onizuka
authors.forename: Maki
authors.initials: M
authors.lastname: Hagihara
authors.forename: Koji
authors.initials: K
authors.lastname: Miyazaki
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Fujita
authors.forename: Rika
authors.initials: R
authors.lastname: Sakai
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Machida
authors.forename: Eri
authors.initials: E
authors.lastname: Tanaka
authors.forename: Yuki
authors.initials: Y
authors.lastname: Nakajima
authors.forename: Yukako
authors.initials: Y
authors.lastname: Hattori
authors.forename: Masatsugu
authors.initials: M
authors.lastname: Tanaka
authors.forename: Etsuko
authors.initials: E
authors.lastname: Yamazaki
authors.forename: Yukari
authors.initials: Y
authors.lastname: Shirasugi
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Inoue
authors.forename: Shigeki
authors.initials: S
authors.lastname: Watanabe
authors.forename: Shin
authors.initials: S
authors.lastname: Fujisawa
mesh_terms: D000293:Adolescent; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D002891:Chromosomes, Human, Pair 21 / Q000235:genetics*; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics*; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000401:mortality / Q000628:therapy*; D060046:Maintenance Chemotherapy; D008297:Male; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D014178:Translocation, Genetic; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine